Research programme: follicle stimulating hormone - Protalix BioTherapeuticsAlternative Names: PRX-111; PRX-113
Latest Information Update: 04 Jul 2014
At a glance
- Originator Protalix Biotherapeutics
- Developer Protalix BioTherapeutics
- Class Hormones
- Mechanism of Action Hormone modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Infertility
Most Recent Events
- 04 Jul 2014 Early research is ongoing in Israel